페그인터페론과 리바비린 병합요법 중 발생한 피부 유육종증 1예
A Case of Cutaneous Sarcoidosis Associated with Pegylated Interferon Alpha-2a and Ribavirin Therapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
만성 C형 간염 환자 치료에 있어서 페그인터페론과 리바비린을 병합하여 치료하는 것이 표준치료이다. 페그인터페론과 리바비린 병합치료 후에 발생하는 부작용으로는 인플루엔자 유사 증상, 불면증, 탈모, 우울증, 빈혈 등이 있으며, 피부에 발생하는 부작용으로는 소양감과 피부염이 알려져 있다. 그러나 피부에 발생한 유육종증은 국내의 경우 아직 보고된 바가 없다. 저자들은 만성 C형 간염 환자에서 페그인터페론과 리바비린의 병합요법 중에 피부에 발생하였고, 자연 치유된 유육종증 1예를 경험하였기에 이를 보고하는 바이다.
Abstract
Pegylated interferon plus ribavirin is the standard treatment regimen in chronic hepatitis C. The main adverse events of pegylated interferon plus ribavirin combination therapy are bone marrow depression, alopecia, insomnia, and influenza-like symptoms. However, there are few reports of cutaneous sarcoidosis occurring during pegylated interferon alpha-2a and ribavirin therapy. Here, we report a case of cutaneous sarcoidosis induced by pegylated interferon alpha-2a and ribavirin during the treatment for chronic hepatitis C. The patient’s sarcoidosis improved spontaneously after the treatment. (Korean J Med 2011;80:S117-S120)
참고문헌 (15)
- Hurst EA, "Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature", Arch Dermatol, 141, pp.865~868 (2005)
- Hoofnagle JH, "Peginterferon and ribavirin for chronic hepatitis C", N Engl J Med, 355, pp.2444~2451 (2006)
- Hadziyannis SJ, "Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- 장혜정, "만성활동성C형간염에 대한 인터페론 치료 후 사르코이드증의", Tuberculosis and Respiratory Diseases, 61(3), pp.285~288 (2006), 대한결핵및호흡기학회
- McHutchison JG, "Understanding hepatitis C", Am J Manag Care, 10(2 Suppl), pp.S21~S29 (2004)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial", Lancet, 358, pp.958~965 (2001)
- Poynard T, "Viral hepatitis C", Lancet, 362, pp.2095~2100 (2003)
- Cogrel O, "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases", Br J Dermatol, 146, pp.320~324 (2002)
- Abdi EA, "Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma", Cancer, 59, pp.896~900 (1987)
- Braverman IM, "Fitzpatrick’s Dermatology in General Medicine. 6th ed" (2003), McGraw-Hill
- Parronchi P, "Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells", Eur J Immunol, 26, pp.697~703 (1996)
- Perez-Alvarez R, "Sarcoidosis in 2 patients with chronic hepatitis C treated with interferon, ribavirin, and amantadine", J Viral Hepat, 9, pp.75~79 (2002)
- Wendling J, "Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C", Arch Dermatol, 138, pp.546~547 (2002)
- Gitlin N, "Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases", Eur J Gastroenterol Hepatol, 14, pp.883~885 (2002)
- Rogers CJ, "Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C", J Am Acad Dermatol, 50, pp.649~650 (2004)